PT - JOURNAL ARTICLE AU - Song, Fujian AU - Bachmann, Max O. TI - Vaccination against COVID-19 and society’s return to normality in England: a modelling study of impacts of different types of naturally acquired and vaccine induced immunity AID - 10.1101/2021.05.18.21257314 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.18.21257314 4099 - http://medrxiv.org/content/early/2021/05/18/2021.05.18.21257314.short 4100 - http://medrxiv.org/content/early/2021/05/18/2021.05.18.21257314.full AB - Objectives To project impacts of mass vaccination against COVID-19, and investigate possible impacts of different types of naturally acquired and vaccine-induced immunity on future dynamics of SARS-CoV-2 transmission from 2021 to 2029 in England.Design Deterministic, discrete-time population dynamic modelling.Participants Population in England.Interventions mass vaccination programmes.Outcome measures daily and cumulative number of deaths from COVID-19.Results If vaccine efficacy is ≥ 70%, the vaccine-induced sterilising immunity lasts ≥ 182 days, and the reinfectivity is greatly reduced (by ≥ 40%), mass vaccination programmes can prevent further COVID-19 outbreaks in England. Under such optimistic scenarios, the cumulative number of COVID-19 deaths is estimated to be from 113,000 to 115,000 by the end of 2029 in England. However, under plausible scenarios with lower vaccine efficacy, shorter durability of immunity, and smaller reduction in reinfectivity, repeated vaccination programmes could not prevent further COVID-19 outbreaks.Conclusions Under optimistic scenarios, mass immunisation using efficacious vaccines may enable society safely to return to normality. However, under plausible scenarios with low vaccine efficacy and short durability of immunity, COVID-19 could continue to cause recurrent waves of severe morbidity and mortality despite frequent vaccinations. It is crucial to monitor the vaccination effects in the real world, and to better understand characteristics of naturally acquired and vaccine induced immunity against SARS-CoV-2.Strengths and limitations of this studyWe used a population dynamic model to assess impacts of vaccination programmes on future dynamics of SARS-CoV-2 transmission dynamics, and to explicitly investigate the impacts of different types of immune responses to SARS-CoV-2 infection and vaccines on the COVID-19 epidemic in England.The model has been verified based on historically observed outcome data in England, and a large number of projection scenarios are explored.Findings from our study improves the understanding of key immunological parameters relevant to future SARS-CoV-2 transmission dynamics and vaccination strategies.This is a deterministic simulation model, and uncertainty in estimated parameters may have not been fully accommodated. There remain many uncertainties regarding durability and types of naturally acquired and vaccine-induced immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as online supplementary information.